8-K: Myriad Genetics: Preliminary Q4/FY25 & FY26 Outlook

Myriad Genetics announced select unaudited preliminary results for the fourth quarter and full year 2025 and provided full year 2026 financial guidance.

Summary

• Preliminary total revenues for the fourth quarter of 2025 are expected to be between $207 million and $209 million.
• Preliminary total revenues for the full year 2025 are expected to be between $822 million and $824 million.
• Total test volumes for full year 2025 are approximately 1.5 million, representing a 1% year-over-year increase.
• Hereditary cancer testing volume grew approximately 7% year-over-year in 2025.
• Mental health testing volume grew approximately 6% year-over-year in 2025.
• Prenatal health testing volume decreased approximately 4% year-over-year in 2025.
• Full year 2026 revenue guidance is set between $860 million and $880 million, with the mid-point reflecting an approximate 6% increase over the preliminary 2025 mid-point.
• Full year 2026 adjusted gross margin guidance is between 68% and 69%, incorporating anticipated new product launches.
• Full year 2026 adjusted EBITDA guidance is between $37 million and $49 million, with the mid-point expected to grow approximately 43% over the mid-point of the previous full year 2025 guidance range.

Sentiment

Score: 8

Explanation: The filing presents a positive outlook with strong 2026 financial guidance, particularly the significant projected growth in adjusted EBITDA and overall revenue. While 2025 results are preliminary and one segment saw a slight decline, the forward-looking statements indicate robust performance expectations.

Positives

• Strong full year 2026 revenue guidance, with a mid-point increase of approximately 6% over preliminary 2025 figures.
• Significant projected growth in full year 2026 adjusted EBITDA, with the mid-point expected to increase by approximately 43% over previous 2025 guidance.
• Positive year-over-year growth in total test volumes for 2025 (1%), driven by hereditary cancer testing (7%) and mental health testing (6%).
• Anticipated impact from new product launches is incorporated into the 2026 adjusted gross margin guidance of 68%-69%.

Negatives

• Preliminary financial results for Q4 and FY 2025 are unaudited and subject to change following normal accounting procedures and external audit.
• Prenatal health testing volume experienced an approximate 4% year-over-year decrease in 2025.

Risks

• Sales and profit margins of existing tests may decline.
• Inability to operate the business on a profitable basis.
• Changes in financial results from preliminary to final audited results for Q4 and FY 2025.
• Inability to achieve certain revenue growth targets or generate sufficient revenue from existing or new products.
• Risks related to recent changes in the company's senior management team and the successful implementation of its strategic plan.
• Changes in governmental or private insurers' coverage and reimbursement levels for tests, or inability to obtain reimbursement for new tests.
• Increased competition and the development of new competing tests.
• Inability to develop or achieve commercial success for additional tests in a timely manner.
• Inability to secure additional financing to fund the business, if needed, in a timely manner or on favorable terms.
• Inability to successfully develop new markets or channels for tests.
• Termination or inability to maintain licenses to the technology underlying tests on satisfactory terms.
• Delays or other problems with operating laboratory testing facilities.
• Public concern over genetic testing in general or the company's tests in particular.
• Regulatory requirements or enforcement changes in the United States and foreign countries, and changes in healthcare system structure or payment systems.
• Inability to obtain new corporate collaborations or licenses, or acquire or develop new technologies or businesses on satisfactory terms.
• Inability to successfully integrate and derive benefits from any licensed, acquired, or developed technologies or businesses.
• Inaccuracy of projections or estimates about the potential market opportunity for current and future products.
• Inability to protect proprietary technologies or infringement by third parties.
• Patent-infringement claims or challenges to the validity of patents.
• Changes in intellectual property laws covering tests, patents, or enforcement.
• Security breaches, loss of data, and other disruptions, including from cyberattacks.
• New, changing, and competitive technologies; inability to keep pace with rapid technology changes or leverage new technologies for competitive advantages.
• Inability to comply with financial or operating covenants under credit or lending agreements.
• Inability to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Current and future investigations, claims, or lawsuits, including derivative claims, product or professional liability claims, and risks related to insurance coverage limits and scope.

Future Outlook

Myriad Genetics anticipates continued growth into 2026, projecting full year revenues between $860 million and $880 million, representing a 6% increase at the mid-point compared to preliminary 2025 results. The company also expects a significant increase in adjusted EBITDA, with the mid-point of guidance reflecting approximately 43% growth over the previous full year 2025 guidance mid-point, driven by new product launches and operational efficiencies.

Management Comments

• The company expects fourth quarter 2025 total revenues to be between $207 million and $209 million.
• The company expects full year 2025 total revenues to be between $822 million to $824 million.
• The mid-point of the 2026 revenue guidance range reflects an increase of approximately 6% compared to the mid-point of the preliminary 2025 revenue range.
• The 2026 adjusted gross margin range incorporates the anticipated impact from new product launches.
• The mid-point of the adjusted EBITDA range is expected to grow approximately 43% over the mid-point of the previous full year 2025 guidance range.

Industry Context

na

Stakeholder Impact

• Shareholders may anticipate increased value due to projected revenue and significant EBITDA growth in 2026.
• Customers may benefit from new product launches incorporated into the 2026 gross margin guidance, potentially indicating expanded or improved testing options.

Next Steps

• Myriad Genetics will present these preliminary results via a live webcast on January 14, 2026, at the 44th Annual J.P. Morgan Healthcare Conference.
• The company plans to release its actual financial results for the fourth quarter and full year 2025 during its earnings call in February 2026.

Key Dates

Recommendation

The strong full year 2026 financial guidance, particularly the projected 43% growth in adjusted EBITDA and 6% revenue increase, suggests a positive trajectory for Myriad Genetics. Despite the preliminary nature of 2025 results and a slight decline in one testing segment, the overall outlook for growth in key areas like hereditary cancer and mental health testing, coupled with new product launches, indicates a compelling investment opportunity for growth-oriented investors.

Keywords

Myriad Genetics, MYGN, molecular diagnostics, precision medicine, genetic testing, financial results, revenue, EBITDA, guidance, Q4 2025, FY 2025, FY 2026, hereditary cancer, mental health testing, prenatal health